Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II clinical trial (RCT), offering an early signal that could reshape how advanced ...

Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II ...

The trial enrolled patients who received a triplet chemotherapy regimen of nab-paclitaxel, cisplatin, and gemcitabine.

Objective To synthesise the evidence regarding the risks and benefits of physical activity (PA), prescribed aerobic exercise treatment, rest, cognitive activity and sleep during the first 14 days ...

Biomerica, Inc. (NASDAQ: BMRA) shares were slightly down Thursday. The company, an innovator in diagnostic-guided therapy, today announced responder analysis results from its ongoing real-world study ...

Physician Interview Now AvailableKey Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized ...

BACKGROUND: The therapeutic effects of cannabinoid compounds have been the center of many investigations. This study provides a synthesis on all Cochrane systematic reviews (SRs) that assessed the use ...

Objective Biologics for systemic lupus erythematosus (SLE) demonstrate variable treatment responses across trials. We evaluated baseline biomarkers as predictors of response to guide personalised ...

RedCloud Holdings plc (NASDAQ: RCT) ("RedCloud" or the "Company"), the technology company building AI infrastructure for global trade, today announced the appointment of Raju Datla as Chief Financial ...

This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas such ...